Our findings suggested a potential clinical benefit by increasing sTILs infiltration and the activation of tumor immune microenvironment by using novel therapeutic agents such as ADCs and immunotherapy, especially in those ER‐negative/HER2‐low, who had significantly inferior survival, warranting further exploration and translational analysis in clinical use. This evidence concerns the gene ERBB2 and neoplasm.